对人类施用白细胞介素-7会导致CD8+和CD4+细胞扩增，但CD4+调节性T细胞相对减少。
IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells.
作者信息
Rosenberg Steven A, Sportès Claude, Ahmadzadeh Mojgan, Fry Terry J, Ngo Lien T, Schwarz Susan L, Stetler-Stevenson Maryalice, Morton Kathleen E, Mavroukakis Sharon A, Morre Michel, Buffet Renaud, Mackall Crystal L, Gress Ronald E
机构信息
Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1201, USA.
出版信息
J Immunother. 2006 May-Jun;29(3):313-9. doi: 10.1097/01.cji.0000210386.55951.c2.
Abstract
Lymphopenia is a serious consequence of HIV infection and the administration of cancer chemotherapeutic agents. Although growth factors can be administered to patients to increase circulating neutrophils, there is no effective method to stimulate CD8+ lymphocyte production in humans, in vivo. This report is the first to describe the administration of recombinant interleukin-7 to humans and demonstrates the ability of this cytokine to mediate selective increases in CD4+ and CD8+ lymphocytes along with a decrease in the percentage of CD4+ T-regulatory cells. These studies suggest an important role for interleukin-7 in the treatment of patients with lymphopenia.
摘要
淋巴细胞减少是HIV感染和癌症化疗药物给药的严重后果。尽管可以给患者使用生长因子以增加循环中的中性粒细胞，但在人体内，目前尚无有效方法来刺激CD8+淋巴细胞的产生。本报告首次描述了重组白细胞介素-7在人体中的给药情况，并证明了这种细胞因子能够介导CD4+和CD8+淋巴细胞的选择性增加，同时降低CD4+调节性T细胞的百分比。这些研究表明白细胞介素-7在淋巴细胞减少患者的治疗中具有重要作用。
相似文献
1
IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells.对人类施用白细胞介素-7会导致CD8+和CD4+细胞扩增，但CD4+调节性T细胞相对减少。
J Immunother. 2006 May-Jun;29(3):313-9. doi: 10.1097/01.cji.0000210386.55951.c2.
2
IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection.白细胞介素-7的施用可推动HIV-1感染中T细胞进入细胞周期并实现扩增。
Blood. 2009 Jun 18;113(25):6304-14. doi: 10.1182/blood-2008-10-186601. Epub 2009 Apr 20.
3
4
Interleukin-7 promotes human regulatory T cell development at the CD4+CD8+ double-positive thymocyte stage.白细胞介素-7 在 CD4+CD8+ 双阳性胸腺细胞阶段促进人类调节性 T 细胞的发育。
J Leukoc Biol. 2016 Sep;100(3):491-8. doi: 10.1189/jlb.1A0415-164R. Epub 2016 Mar 10.
5
Selective Activation of Tumor Necrosis Factor Receptor II Induces Antiinflammatory Responses and Alleviates Experimental Arthritis.肿瘤坏死因子受体 II 的选择性激活诱导抗炎反应并缓解实验性关节炎。
Arthritis Rheumatol. 2018 May;70(5):722-735. doi: 10.1002/art.40413. Epub 2018 Mar 11.
6
Oscillatory mTOR inhibition and Treg increase in kidney transplantation.肾移植中振荡性mTOR抑制与调节性T细胞增加
Clin Exp Immunol. 2015 Nov;182(2):230-40. doi: 10.1111/cei.12669. Epub 2015 Aug 28.
7
CD8 T cells drive autoimmune hematopoietic stem cell dysfunction and bone marrow failure.CD8 T细胞驱动自身免疫性造血干细胞功能障碍和骨髓衰竭。
J Autoimmun. 2016 Dec;75:58-67. doi: 10.1016/j.jaut.2016.07.007. Epub 2016 Jul 21.
8
Effects of arsenic disulfide on proliferation, cytokine production, and frequencies of CD4(+), CD8(+), and regulatory T cells in mitogen-activated human peripheral blood mononuclear cells.二硫化砷对丝裂原激活的人外周血单个核细胞的增殖、细胞因子产生以及CD4(+)、CD8(+)和调节性T细胞频率的影响
Int Immunopharmacol. 2015 Dec;29(2):832-838. doi: 10.1016/j.intimp.2015.08.034. Epub 2015 Sep 8.
9
IL-7 enhances the responsiveness of human T cells that develop in the bone marrow of athymic mice.白细胞介素-7增强了在无胸腺小鼠骨髓中发育的人类T细胞的反应性。
J Immunol. 2001 Jan 1;166(1):170-81. doi: 10.4049/jimmunol.166.1.170.
10
Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells.替西木单抗（抗 CTLA-4）主要通过直接激活效应 T 细胞而不是通过影响 T 调节细胞来介导免疫反应。
Clin Immunol. 2011 Jan;138(1):85-96. doi: 10.1016/j.clim.2010.09.011. Epub 2010 Nov 5.
引用本文的文献
1
Immunosenescence: signaling pathways, diseases and therapeutic targets.免疫衰老：信号通路、疾病与治疗靶点。
Signal Transduct Target Ther. 2025 Aug 6;10(1):250. doi: 10.1038/s41392-025-02371-z.
2
Evaluation of Cytokine Profile in Canine Malignant Oral Melanoma.犬恶性口腔黑色素瘤细胞因子谱的评估
Vet Sci. 2025 Jun 30;12(7):627. doi: 10.3390/vetsci12070627.
3
Boosting anti-tumor immunity with TILT-517 oncolytic adenovirus and checkpoint blockade in renal cell carcinoma.使用TILT-517溶瘤腺病毒和检查点阻断增强肾细胞癌的抗肿瘤免疫力。
Mol Ther Oncol. 2025 Apr 3;33(2):200979. doi: 10.1016/j.omton.2025.200979. eCollection 2025 Jun 18.
4
Burning Down the House: Thymic Repair and Regeneration After Acute Damage.焚毁房屋：急性损伤后的胸腺修复与再生
Immunol Rev. 2025 Jul;332(1):e70050. doi: 10.1111/imr.70050.
5
Development of an in situ CAR-T cell protocol through optical and PSMA-targeted PET imaging.通过光学和靶向前列腺特异性膜抗原（PSMA）的正电子发射断层扫描（PET）成像开发原位嵌合抗原受体（CAR）-T细胞方案。
Proc Natl Acad Sci U S A. 2025 Jun 17;122(24):e2504950122. doi: 10.1073/pnas.2504950122. Epub 2025 Jun 10.
6
GX-I7, a long-acting IL-7, safely and effectively increased peripheral CD8/CD4 T cells and TILs in patients with locally advanced or metastatic solid tumours.GX-I7是一种长效白细胞介素-7，可安全有效地增加局部晚期或转移性实体瘤患者的外周CD8/CD4 T细胞及肿瘤浸润淋巴细胞。
Br J Cancer. 2025 Jun 9. doi: 10.1038/s41416-025-03069-3.
7
Endogenous IL-7 Variation in Relation to Lymphocyte Subtypes in Septic Patients.脓毒症患者内源性白细胞介素-7与淋巴细胞亚群的关系
Medicina (Kaunas). 2025 Feb 2;61(2):258. doi: 10.3390/medicina61020258.
8
Phase I study of efineptakin alfa (NT-I7) for the treatment of Kaposi sarcoma.阿法依那西普（NT-I7）治疗卡波西肉瘤的I期研究。
J Immunother Cancer. 2025 Feb 6;13(2):e010291. doi: 10.1136/jitc-2024-010291.
9
Severe disseminated infection in idiopathic CD4 lymphopenia.特发性CD4淋巴细胞减少症中的严重播散性感染。
IDCases. 2025 Jan 6;39:e02148. doi: 10.1016/j.idcr.2025.e02148. eCollection 2025.
10
Tumor cells ectopically expressing the membrane-bound form of IL-7 develop an antitumor immune response efficiently in a colon carcinoma model.在结肠癌模型中，异位表达膜结合形式白细胞介素-7的肿瘤细胞能有效引发抗肿瘤免疫反应。
Mol Cells. 2025 Feb;48(2):100175. doi: 10.1016/j.mocell.2024.100175. Epub 2024 Dec 30.
本文引用的文献
1
IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.白细胞介素-2的施用可增加癌症患者体内CD4+ CD25(高表达) Foxp3+调节性T细胞的数量。
Blood. 2006 Mar 15;107(6):2409-14. doi: 10.1182/blood-2005-06-2399. Epub 2005 Nov 22.
2
Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells.淋巴细胞减少症和白细胞介素-2疗法会改变CD4+CD25+调节性T细胞的稳态。
Nat Med. 2005 Nov;11(11):1238-43. doi: 10.1038/nm1312. Epub 2005 Oct 16.
3
In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients.在接受白细胞介素-2治疗的HIV感染患者体内，表达foxP3的CD4CD45RO-CD25 T细胞的扩增
J Clin Invest. 2005 Jul;115(7):1839-47. doi: 10.1172/JCI24307. Epub 2005 Jun 2.
4
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.CD4 +辅助性T细胞增强了CD8 + T细胞对肿瘤/自身抗原的免疫反应，而天然存在的调节性T细胞则对其产生阻碍。
J Immunol. 2005 Mar 1;174(5):2591-601. doi: 10.4049/jimmunol.174.5.2591.
5
Cancer immunotherapy: moving beyond current vaccines.癌症免疫疗法：超越现有疫苗
Nat Med. 2004 Sep;10(9):909-15. doi: 10.1038/nm1100.
6
Prospective immunological profiling in a case of immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX).免疫失调、多内分泌腺病、肠病、X连锁综合征（IPEX）病例的前瞻性免疫谱分析。
Clin Exp Immunol. 2004 Aug;137(2):373-8. doi: 10.1111/j.1365-2249.2004.02537.x.
7
A dose effect of IL-7 on thymocyte development.白细胞介素-7对胸腺细胞发育的剂量效应。
Blood. 2004 Sep 1;104(5):1419-27. doi: 10.1182/blood-2004-01-0201. Epub 2004 May 20.
8
Exogenous IL-7 increases recent thymic emigrants in peripheral lymphoid tissue without enhanced thymic function.外源性白细胞介素-7可增加外周淋巴组织中近期胸腺迁出细胞的数量，而不会增强胸腺功能。
Blood. 2004 Aug 15;104(4):1110-9. doi: 10.1182/blood-2003-10-3635. Epub 2004 May 6.
9
Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses.自然产生的CD4+调节性T细胞用于免疫自我耐受和免疫反应的负调控。
Annu Rev Immunol. 2004;22:531-62. doi: 10.1146/annurev.immunol.21.120601.141122.
10
The main function of IL-2 is to promote the development of T regulatory cells.白细胞介素-2的主要功能是促进调节性T细胞的发育。
J Leukoc Biol. 2003 Dec;74(6):961-5. doi: 10.1189/jlb.0603272. Epub 2003 Sep 2.
Zotero 插件